RIT with Y90-Ibritumomab Tiuxetan in Follicular Non-Hodgkin Lymphoma: Evaluation of Recent Outcomes in a Single Institution

Table 2

Schedules preconsolidation.

Treatment preconsolidation	Number of patients	%
R alone ×4	6	27.3
R-CHOP	13	59.1
R-EPOCH	1	4.5
R-COP	2	9.1
Total	22	100

R: Rituximab 375 mg/m².